Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

Objective FOLFIRI is a standard chemotherapy regimen for the treatment of metastatic colorectal cancer. Although some studies have shown its efficacy in combination with bevacizumab as first-line chemotherapy, there are no data to support FOLFIRI plus bevacizumab as second-line chemotherapy in patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2012-12, Vol.17 (6), p.604-609
Hauptverfasser:	Horita, Yosuke, Yamada, Yasuhide, Kato, Ken, Hirashima, Yoshinori, Akiyoshi, Kouhei, Nagashima, Kengo, Nakajima, Takako, Hamaguchi, Tetsuya, Shimada, Yasuhiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bevacizumab Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cancer Research Chemotherapy Clinical outcomes Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Disease-Free Survival Female Fluorouracil - administration & dosage Humans Leucovorin - administration & dosage Male Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Oncology Original Article Pharmacology Surgical Oncology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!